APA (7th ed.) Citation

A, H., X, N., C, C., R, P., P, L., M, B., . . . N, A. (2024). Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clinical and translational science, 17(1), e13690. https://doi.org/10.1111/cts.13690

Chicago Style (17th ed.) Citation

A, Hincelin-Mery, et al. "Safety, Pharmacokinetics, and Target Engagement of a Brain Penetrant RIPK1 Inhibitor, SAR443820 (DNL788), in Healthy Adult Participants." Clinical and Translational Science 17, no. 1 (2024): e13690. https://doi.org/10.1111/cts.13690.

MLA (9th ed.) Citation

A, Hincelin-Mery, et al. "Safety, Pharmacokinetics, and Target Engagement of a Brain Penetrant RIPK1 Inhibitor, SAR443820 (DNL788), in Healthy Adult Participants." Clinical and Translational Science, vol. 17, no. 1, 2024, p. e13690, https://doi.org/10.1111/cts.13690.